The journal of allergy and clinical immunology. Global最新文献

{"title":"Atopic dermatitis and tobacco smoke exposure during childhood and adolescence","authors":"Noor A. Al-Alusi MD, MS ,&nbsp;Faustine D. Ramirez MD ,&nbsp;Leslie N. Chan MD ,&nbsp;Morgan Ye MPH ,&nbsp;Sinéad M. Langan FRCP, MSc, PhD ,&nbsp;Chuck McCulloch PhD ,&nbsp;Katrina Abuabara MD, MA, MSCE","doi":"10.1016/j.jacig.2024.100345","DOIUrl":"10.1016/j.jacig.2024.100345","url":null,"abstract":"<div><h3>Background</h3><div>Tobacco smoke may affect atopic dermatitis (AD) because of its known effects on humoral and cellular immunity, but prior studies lack data on disease severity and biomarkers over time.</div></div><div><h3>Objective</h3><div>We investigated the association between passive and active tobacco smoke exposure (TSE) during childhood and adolescence and the activity and severity of AD.</div></div><div><h3>Methods</h3><div>A birth cohort of 10,521 individuals was followed through adolescence as part of the Avon Longitudinal Study of Parents and Children. We used mixed-effect models to determine the risk of AD (based on repeated assessments) with passive smoke exposure during childhood, active TSE during adolescence, and using a serum biomarker of tobacco exposure (cotinine) at 3 time points.</div></div><div><h3>Results</h3><div>After adjusting for confounding factors, there was no evidence of a relationship between passive TSE and concurrent AD activity in childhood (adjusted odds ratio, 0.95; 95% confidence interval, 0.83, 1.07) or of an increased risk between active smoking and AD activity in adolescence (adjusted odds ratio, 0.57; 95% confidence interval, 0.44, 0.75). Secondary analyses demonstrated no dose–response relationship and no increased severity of AD with passive or active TSE. Furthermore, we found no increased risk of AD with a cumulative measure of passive TSE across childhood (adjusted relative risk ratio, 0.98; 95% confidence interval, 0.96, 1.00).</div></div><div><h3>Conclusion</h3><div>Neither active nor passive TSE was associated with AD during childhood and adolescence.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100345"},"PeriodicalIF":0.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142527298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial and ethnic disparities in dupilumab for pediatric atopic dermatitis in Florida","authors":"Urdur Jonsdottir MD ,&nbsp;Emily S. Craver MS ,&nbsp;Tanvi Patel MD","doi":"10.1016/j.jacig.2024.100344","DOIUrl":"10.1016/j.jacig.2024.100344","url":null,"abstract":"<div><h3>Background</h3><div>Dupilumab is an mAb that has been shown to decrease symptoms and severity of atopic dermatitis (AD). It was approved for use in adolescents and children in a stepwise manner from 2019 to 2022. Racial and ethnic disparities have been described in access to emerging therapies in many conditions, including treatment with dupilumab for AD in adult patients.</div></div><div><h3>Objective</h3><div>We sought to assess racial and ethnic disparities in moderate to severe AD treatment with dupilumab in the pediatric population.</div></div><div><h3>Methods</h3><div>This retrospective study identified 12,918 patients with AD aged 0 to 17 years who had at least a 6-month follow-up period between January 2020 and September 2023. The primary end point of dupilumab prescription was compared between racial and ethnic groups and a reference group of non-Hispanic White patients while adjusting for confounders.</div></div><div><h3>Results</h3><div>Among the patients, 18.1% were Black, 40.5% Hispanic, 28.9% non-Hispanic White, and 12.4% Other race. Black (odds ratio, 0.43; <em>P</em> = .006) and Hispanic (odds ratio, 0.46; <em>P</em> &lt; .001) patients had significantly lower odds of receiving dupilumab compared with the reference group.</div></div><div><h3>Conclusions</h3><div>This study may indicate a racial and ethnic disparity negatively affecting access to treatment with dupilumab for Black and Hispanic children and adolescents with AD. Because previous studies have not indicated decreased severity of AD in these patient populations, less frequent use is likely due to other underlying factors such as differential access to care, cultural differences, language barriers, and socioeconomic factors. The contributing factors must be further identified and addressed to ensure health equity in pediatric AD.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100344"},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinguishing DRESS syndrome from drug rash and eosinophilia: Beyond RegiSCAR criteria","authors":"Grace Thompson MBBS ,&nbsp;Syed Ali MBBS ,&nbsp;Michelle Trevenen PhD ,&nbsp;Philip Vlaskovsky PhD ,&nbsp;Kevin Murray PhD ,&nbsp;Michaela Lucas MD","doi":"10.1016/j.jacig.2024.100346","DOIUrl":"10.1016/j.jacig.2024.100346","url":null,"abstract":"<div><h3>Background</h3><div>Diagnosing drug reaction with eosinophilia and systemic symptoms (DRESS) can be challenging.</div></div><div><h3>Objectives</h3><div>We sought to identify clinical and laboratory features outside of the Registry of Severe Cutaneous Adverse Reaction (RegiSCAR) criteria that distinguish patients with probable DRESS (RegiSCAR ≥ 4) from those with drug rash and eosinophilia (DRE).</div></div><div><h3>Methods</h3><div>Using international coding classifications of drug-induced fever, generalized skin eruption due to medications, and eosinophilia, a retrospective audit from 2008 to 2023 of hospitalized patients was performed.</div></div><div><h3>Results</h3><div>Forty-four cases of DRESS were compared to 80 cases of DRE. In addition to the RegiSCAR distinguishing factors for DRESS were longer drug latency before symptom onset (median 21 vs 5 days, <em>P</em> &lt; .001) and higher alanine transaminase levels (increase by a factor of 2.49 [95% confidence interval, 1.56, 4.00; <em>P</em> = .009]). Follow-up (mean 5.67 years) revealed a low rate of statewide drug alert reporting (29.6%) and drug allergy testing in DRESS (20.5%). Inadvertent reexposure to a culprit or structurally related drug resulted in recurrent DRESS in 3 patients (7.5%), and tolerance of structurally related drugs occurred in 8 patients (17.5%).</div></div><div><h3>Conclusion</h3><div>In this large study evaluating DRE patients whose disease does not meet the RegiSCAR criteria for DRESS, we found that additional factors outside the RegiSCAR criteria may help clinicians differentiate DRESS, which is critical for optimal and timely patient management. Our study also highlights the need for development of local protocols to ensure appropriate allergy labeling and testing are performed to prevent recurrent DRESS.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100346"},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142445507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A RESPONSE to anti–IL-5 therapy in comorbid patients with chronic rhinosinusitis with nasal polyps and severe asthma: Study protocol","authors":"Petros Bakakos PhD ,&nbsp;Isam Alobid PhD ,&nbsp;Jannis Constantinidis PhD ,&nbsp;Peter Hellings PhD ,&nbsp;Oliver Pfaar PhD ,&nbsp;Camille Taillé PhD ,&nbsp;David Bañas-Conejero MSc ,&nbsp;Konstantina Kallinikou PhD ,&nbsp;Peter Howarth DM ,&nbsp;Florence Schleich PhD","doi":"10.1016/j.jacig.2024.100343","DOIUrl":"10.1016/j.jacig.2024.100343","url":null,"abstract":"<div><h3>Background</h3><div>Chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma (SA) are 2 frequently coexisting conditions that are, in most cases, associated with eosinophilic inflammation. The concurrence of both diseases has a negative synergistic impact on disease severity and patients’ health-related quality of life. Thus, a holistic, collaborative management of these patients is a critical unmet need. Mepolizumab, a systemic anti–IL-5 therapy, has been shown to be effective as an add-on treatment in both SA and CRSwNP, with more literature available on asthma outcomes than on CRSwNP.</div></div><div><h3>Objectives</h3><div>The primary objective of the study is to evaluate the real-world effectiveness of mepolizumab in improving the health-related quality of life of comorbid patients at 12 months using the SNOT-22 questionnaire. Secondary objectives include safety and efficacy outcomes of mepolizumab treatment in the 2 populations, which are expected to have variable severity of the respective comorbid conditions.</div></div><div><h3>Methods</h3><div>RESPONSE is a European real-world prospective cohort study designed to assess the effectiveness of mepolizumab in 2 cohorts of adult patients: one with SA as primary diagnosis with (secondary diagnosis) comorbid CRSwNP, and another with CRSwNP as primary diagnosis with (secondary diagnosis) comorbid asthma. Up to 350 patients receiving newly prescribed mepolizumab will be followed up for 12 months as per the investigators’ standard of care.</div></div><div><h3>Conclusion</h3><div>This study will report the effects of anti–IL-5 therapy in both diseases investigated and the respective comorbidity, as well as the consequence of treating milder forms of asthma and CRSwNP with mepolizumab, supporting the emerging evidence on early treatment optimization.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100343"},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142553386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between asthma and IgG levels specific for rhinovirus and respiratory syncytial virus antigens in children and adults","authors":"Marion Mauclin MSc ,&nbsp;Alicia Guillien PhD ,&nbsp;Katarzyna Niespodziana PhD ,&nbsp;Anne Boudier MSc ,&nbsp;Thomas Schlederer PhD ,&nbsp;Maja Bajic MSc ,&nbsp;Peter Errhalt MD ,&nbsp;Kristina Borochova PhD ,&nbsp;Isabelle Pin MD ,&nbsp;Frédéric Gormand MD ,&nbsp;Raphaël Vernet MD ,&nbsp;Jean Bousquet MD, PhD ,&nbsp;Emmanuelle Bouzigon MD, PhD ,&nbsp;Rudolf Valenta MD, PhD ,&nbsp;Valérie Siroux PhD","doi":"10.1016/j.jacig.2024.100342","DOIUrl":"10.1016/j.jacig.2024.100342","url":null,"abstract":"<div><h3>Background</h3><div>Viral infections in childhood, especially to rhinovirus (RV) and respiratory syncytial virus (RSV), are associated with asthma inception and exacerbation. However, little is known about the role of RV- and RSV-specific antibodies in childhood versus adult asthma.</div></div><div><h3>Objective</h3><div>We sought to investigate associations between RV- and RSV-specific IgG levels and asthma phenotypes in children and adults.</div></div><div><h3>Methods</h3><div>The analysis included 1771 samples from participants of the Epidemiological Study on the Genetics and Environment of Asthma (530 children; age [mean ± SD], 11.1 ± 2.8, and 1241 adults; age [mean ± SD], 43.4 ± 16.7, among whom 274 and 498 had ever asthma, respectively). RSV- and RV-specific IgG levels were determined using microarrayed virus-derived antigens and peptides. Cross-sectional associations between standardized RSV- and RV-specific IgG levels and asthma phenotypes were estimated by multiple regression models.</div></div><div><h3>Results</h3><div>In children, ever asthma was associated with higher IgG levels specific to RV, especially to RV-A and RV-C, and to RSV (adjusted odds ratios [95% CI] for a 1 − SD increase in IgG levels were 1.52 [1.16-1.99], 1.42 [1.10-1.83], and 1.24 [0.99-1.54], respectively). These associations were stronger for moderate to severe asthma than for mild asthma. Conversely in adults, ever asthma was associated with lower RV-A, RV-B, and RV-C IgG levels (adjusted odds ratios [95% CI] were 0.86 [0.74-0.99], 0.83 [0.73-0.95], and 0.85 [0.73-0.99], respectively).</div></div><div><h3>Conclusions</h3><div>Our results suggest that the association between respiratory virus–specific antibody levels and asthma varies during life, with asthma associated with higher levels of IgG to RSV, RV-A, and RV-C in children and lower levels of IgG responses to RV-A/B/C in adults.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"4 1","pages":"Article 100342"},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142527297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of nonpharmaceutical interventions during COVID-19 pandemic on pediatric asthma exacerbations and viral infections","authors":"Katherine Caid MD ,&nbsp;Megan Tate MD ,&nbsp;Shahwar Yousuf MD ,&nbsp;Lillian Jones BS ,&nbsp;Robert D. Pesek MD ,&nbsp;Akilah A. Jefferson MD, MSc ,&nbsp;Tamara T. Perry MD ,&nbsp;Daniel Liu MD ,&nbsp;Grace Turner BA ,&nbsp;Ashton Ingold BS ,&nbsp;Susanna Hartzell BA ,&nbsp;Bobby L. Boyanton Jr. MD ,&nbsp;Kim Cobb MA, RRT-NPS, AE-C ,&nbsp;Haley Long BS, RRT, A-EC ,&nbsp;Suzanne House BA ,&nbsp;Dana Frederick MS ,&nbsp;Rachel A. Frenner MHA ,&nbsp;Erin Hathorn MSHI ,&nbsp;Jing Jin PhD ,&nbsp;Scott Stewart MS ,&nbsp;Joshua L. Kennedy MD","doi":"10.1016/j.jacig.2024.100340","DOIUrl":"10.1016/j.jacig.2024.100340","url":null,"abstract":"<div><h3>Background</h3><div>The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in March 2020 led to the implementation of nonpharmaceutical interventions (NPIs) to curb its spread. Studies have shown that adult asthma exacerbations and viral infections decreased during NPI use. However, few studies have shown the effects of NPIs on pediatric asthma exacerbations and infections during and after the pandemic.</div></div><div><h3>Objective</h3><div>This study aimed to understand the impact of NPIs on asthma exacerbations and viral respiratory infections in pediatric patients at our institution from March 2018 to December 2022.</div></div><div><h3>Methods</h3><div>The medical record numbers of children with asthma exacerbations seen at our institution between March 2018 and December 2022 were analyzed. Subjects were categorized on the basis of timing of their exacerbation in relation to NPI enforcement. We used the results from clinical testing with the BioFire Respiratory Panel (BRP) to detect up to 22 respiratory pathogens and then correlated these results with asthma exacerbation severity.</div></div><div><h3>Results</h3><div>There were 5,758 asthma exacerbations recorded, with a 50% decline in average weekly exacerbations during NPI enforcement. Of the 70,682 BRP tests performed, 87% returned a positive result for at least 1 pathogen. Several viruses (respiratory syncytial virus, parainfluenza, and influenza) had a decrease in positivity rate with NPIs, whereas rhinovirus/enterovirus positivity rates were unchanged throughout the pandemic. Asthma exacerbations with a positive BRP result required higher clinical levels of care during the admission.</div></div><div><h3>Conclusion</h3><div>NPIs were associated with significantly reduced numbers of asthma exacerbations and respiratory viral infections. The post-NPI period saw a return to prepandemic levels of asthma exacerbations and an unusual surge in respiratory syncytial virus infections, emphasizing the need for continuous monitoring and adaptive strategies in the postpandemic landscape.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100340"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142533198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The triple radiologic asthma phenotype is associated with worse disease control","authors":"Rory Chan MBChB, PhD ,&nbsp;Chary Duraikannu FRCR ,&nbsp;Mohamed Jaushal Thouseef FRCR ,&nbsp;Brian Lipworth MD","doi":"10.1016/j.jacig.2024.100341","DOIUrl":"10.1016/j.jacig.2024.100341","url":null,"abstract":"<div><h3>Background</h3><div>Efforts have been made to combine radiographic biomarkers such as bronchiectasis or bronchial wall thickness (BWT) for the purpose of identifying asthma subphenotypes and their clinical implications.</div></div><div><h3>Objective</h3><div>Our aim was to assess whether a composite triple radiologic phenotype measured by high-resolution computed tomography comprising BWT, mucus plug score (MPS), and mediastinal lymph node (MLN) size might provide a better insight into subphenotypes in persistent asthma.</div></div><div><h3>Methods</h3><div>A total of 112 patients with moderate-to-severe asthma were included in this retrospective observational study. A binary method was used to classify patients according to median values for the following: a pooled mediastinal lymph node size of 3.6 mm or more; a BWT as a pooled wall area of at least 50% of the total airway area; and a mucus plug score of 1 or higher, with a mucus plug considered positive if complete bronchial obstruction was imaged more than 2 cm from a pleural surface.</div></div><div><h3>Results</h3><div>Patients with the triple imaging phenotype exhibited significantly worse Asthma Control Questionnaire scores, with their scores exceeding minimal clinical important difference, a higher prevalence of concomitant chronic rhinosinusitis with nasal polyps, and a greater total IgE level.</div></div><div><h3>Conclusion</h3><div>We have demonstrated an association between poorer symptom control and the triple radiologic asthma phenotype.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100341"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 vaccine","authors":"Amin Esmailian BSC (Hons), MD ,&nbsp;Sara Laura Barnes MBBS (Hons), MBA, FRACP, ADJAOP ,&nbsp;Marsus Pumar BBiomedSc (Hons), BMBS, MPhil","doi":"10.1016/j.jacig.2024.100339","DOIUrl":"10.1016/j.jacig.2024.100339","url":null,"abstract":"<div><div>We present a case of secondary T-cell deficiency particularly affecting CD4 T cells, along with the emergence of chronic spontaneous urticaria in a patient following COVID-19 vaccination. The condition was partially managed with omalizumab after initial first-line therapy proved ineffective.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100339"},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001358/pdfft?md5=18984cb165c25986a8596a564a6b8786&pid=1-s2.0-S2772829324001358-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142314326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of cardiovascular events in a population-based Danish cohort with atopic dermatitis","authors":"Alexander Egeberg MD, PhD ,&nbsp;Andreas Wollenberg MD ,&nbsp;Thomas Bieber MD, PhD ,&nbsp;Adina R. Lemeshow PhD ,&nbsp;Shefali Vyas MD","doi":"10.1016/j.jacig.2024.100338","DOIUrl":"10.1016/j.jacig.2024.100338","url":null,"abstract":"<div><h3>Background</h3><div>The risk of cardiovascular disease in atopic dermatitis (AD) is not well established.</div></div><div><h3>Objectives</h3><div>Our aims were to evaluate the incidence rate (IR) of venous thromboembolism (VTE) in patients with AD in a population-based cohort study and to assess atherosclerotic cardiovascular disease (ASCVD) risk factors and incidence of malignancies, major adverse cardiovascular events (MACE), and VTE in patients with AD and rheumatoid arthritis (RA) in a nested cohort analysis.</div></div><div><h3>Methods</h3><div>Data from individuals age 12 years or older (nested cohort age ≥ 18 years) from January 1, 2000, to December 31, 2018, were extracted from the Danish National Patient Registry. Patients with AD were age- and sex-matched with 10 healthy controls. ASCVD risk factors included age 65 years or older and history of smoking, coronary artery disease, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and malignancy.</div></div><div><h3>Results</h3><div>The population-based cohort comprised 190,751 patients (17,341 patients with AD and 173,410 healthy controls). The IRs per 100 patient-years were comparable between the AD cohort and healthy controls for VTE (0.14 [95% CI = 0.12-0.16] vs 0.11 [95% CI = 0.11-0.12]), DVT (0.08 [95% CI = 0.06-0.09] vs 0.06 [95% CI = 0.06-0.07]), and PE (0.06 [95% CI = 0.05-0.08] vs 0.05 [95% CI = 0.05-0.05]). The IR for VTE was higher in the AD cohort age 65 years or older (0.71 [95% CI = 0.56-0.90]) than in the age-matched controls (0.50 [95% CI = 0.46-0.54]). ASCVD risk factors were more frequent in the patients with RA than in the patients with AD. The IRs for malignancies and MACE were higher with specific ASCVD risk factors.</div></div><div><h3>Conclusions</h3><div>The IRs of cardiovascular events were comparable between the AD cohort and general population. The risk of VTE, malignancy, or MACE was higher with specific ASCVD risk factors, underscoring the need for patient monitoring.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100338"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142326999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboxymethylcellulose: A hidden culprit in immediate hypersensitivity reactions after triamcinolone injections","authors":"Aiwei Yan MD ,&nbsp;Edward Fernandez MD ,&nbsp;Matthew Steven Krantz MD ,&nbsp;Basil M. Kahwash MD ,&nbsp;Elizabeth J. Phillips MD ,&nbsp;Cosby A. Stone Jr. MD, MPH","doi":"10.1016/j.jacig.2024.100337","DOIUrl":"10.1016/j.jacig.2024.100337","url":null,"abstract":"<div><div>We aim to bring awareness of allergies to excipients such as carboxymethylcellulose as “hidden dangers” that can be easily missed in diagnosis, leading to severe effects on patient health, and falsely limit the drug treatments that a patient can receive.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100337"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001334/pdfft?md5=23fef908c2b03bf14f54458265c5a4f2&pid=1-s2.0-S2772829324001334-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}